Plasma miR-513a-5p as a Potential Biomarker for Diagnosis of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus Patients

被引:5
|
作者
Li, Fuwu [1 ]
Wu, Xiyao [2 ]
Zhang, Yan [1 ]
Wei, Kaijun [1 ]
机构
[1] Jinan Fifth Peoples Hosp, Phys Examinat Ctr, 24297 Jingshi Rd, Jinan, Shandong, Peoples R China
[2] Shandong Prov Third Hosp, Ultrasound Dept, Jinan, Shandong, Peoples R China
关键词
type 2 diabetes mellitus; nonalcoholic fatty liver; miR-513a-5p; lipid metabolism; insulin resistance; PERIPHERAL-BLOOD; EXPRESSION; RISK; INCREASES; SERVE;
D O I
10.7754/Clin.Lab.2019.190907
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The current study aims to investigate the relationship between plasma levels of miR-513a-5p and lipid metabolism and insulin resistance in patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Methods: Two hundred patients with T2DM were selected, including 104 patients with NAFLD diagnosed by ultrasound and 96 patients without NAFLD. They were divided into combined group (T2DM/NAFLD) and control group (T2DM). Height, weight, blood lipid, and blood sugar were measured. Additionally, body mass index (BMI) and homeostasis model assessment of insulin resistance (HOMA-IR) index were calculated. RT-PCR was carried out to analyze the level of plasma miR-513a-5p. The correlation between plasma miR-513a-5p level and clinical indicators was analyzed by Pearson's correlation assay. Results: Compared with the T2DM group, BMI, AST, ALT, TG, GGT, LDL-C, 2hPBG, Fins, 2hIns, HbAIc (%), and HOMA-IR were significantly increased in the T2DM/NAFLD group, and plasma miR-513a-5p levels were significantly decreased. Pearson's correlation analysis showed that miR-513a-5p was negatively correlated with ALT, LDL-C, 2h Ins, and HomA-IR Receiver operating characteristic (ROC) analysis showed plasma miR-513a-5p could differentiate T2DM/NAFLD patients from NAFLD patients. Conclusions: Decreased plasma miR-513a-5p level may act as a potential biomarker for diagnosis of NAFLD in T2DM patients.
引用
收藏
页码:787 / 792
页数:6
相关论文
共 50 条
  • [1] Nonalcoholic fatty liver disease in type 2 diabetes mellitus
    Cusi, Kenneth
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2009, 16 (02) : 141 - 149
  • [2] The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    Dai, Chia-Yen
    Fang, Tzu-Jung
    Hung, Wei-Wen
    Tsai, Hui-Ju
    Tsai, Yi-Chun
    BIOMEDICINES, 2022, 10 (07)
  • [3] Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
    Paola Portillo-Sanchez
    Kenneth Cusi
    Clinical Diabetes and Endocrinology, 2 (1):
  • [4] The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Miyasato, Mai
    Murase-Mishiba, Yuko
    Bessho, Megumi
    Miyawaki, Masahiro
    Imbe, Hisashi
    Tsutsumi, Chiharu
    Tanimoto, Keiji
    Imagawa, Akihisa
    Terasaki, Jungo
    Hanafusa, Toshiaki
    CLINICA CHIMICA ACTA, 2014, 433 : 184 - 189
  • [5] Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Wang, Cong
    He, Miao
    Peng, Jiajia
    Li, Shengbing
    Long, Min
    Chen, Wenwen
    Liu, Dongfang
    Yang, Gangyi
    Zhang, Lili
    CYTOKINE, 2020, 125
  • [6] Role of type 2 diabetes mellitus in nonalcoholic fatty liver disease
    Filik, L.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2011, 41 (12) : 1367 - 1367
  • [7] The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    Kosmalski, Marcin
    Ziolkowska, Sylwia
    Czarny, Piotr
    Szemraj, Janusz
    Pietras, Tadeusz
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
  • [8] Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment
    Ciardullo, Stefano
    Vergani, Michela
    Perseghin, Gianluca
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (17)
  • [9] Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
    Younossi, Zobair M.
    Gramlich, Terry
    Matteoni, Christi A.
    Boparai, Navdeep
    Mccullough, Arthur J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (03) : 262 - 265
  • [10] Use of Plasma Metabolomics and Lipidomics for the Diagnosis of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes
    Bril, Fernando
    Kalavalapalli, Srilaxmi
    Duffin, Kevin L.
    Hartman, Mark L.
    Chen, Yu
    Yang, Qian
    Haas, Joseph V.
    Milligan, Paul L., Jr.
    Roth, Kenneth D.
    Cusi, Kenneth
    DIABETES, 2018, 67